NEW YORK (360Dx) – Oxford Immunotec today reported relatively flat revenues for its first quarter compared to a year ago, primarily due to lower test utilization related to immigrant screening.

For the three months ended March 31, total revenues were $21.4 million, slightly down from $21.5 million a year ago, and above the consensus Wall Street estimate of $21.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.